# Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers

> **NCT02211937** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 25 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 44847 solution, low dose
- **DRUG:** BI 44847 suspension, high dose
- **DRUG:** BI 44847 tablet, low dose
- **DRUG:** BI 44847 tablet, high dose
- **OTHER:** high fat breakfast

## Key facts

- **NCT ID:** NCT02211937
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2007-03
- **Final completion:** —
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2014-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02211937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02211937, "Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02211937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*